developed a vaccine containing MUC1 antigen and TLR7 agonist, significantly enhancing the immune response against MUC1-expressing tumors, increasing antibody titers and T cell activity, indicating its potential in breast cancer treatment (167). This evidence concerns the gene TLR7 and breast carcinoma.